Skip to NavigationSkip to content

Roche's Tecentriq improves pathological complete response in triple-negative breast cancer at Phase 3

Published on 19/06/20 at 10:45am


Genentech and Roche have released new Phase 3 on the efficacy of their immunotheraoy drug Tecentriq (atezolizumab), when used in combination with Abraxane chemotherapy followed by doxorubicin and cyclophosphamide, in the treatment of early triple-negative breast cancer (TNBC), regardless of PD-L1 expression.

The new data revealed that, after 21 weeks of treatment, patients receiving Tecentriq prior to surgery were less likely to display evidence of detectable tumour tissue at the time of surgery regardless of their PD-L1 expression compared to those receiving the placebo combo.

According to the findings, Tecentriq generated a “statistically significant and clinically meaningful improvement in pathological complete response (pCR)”, as measured on the American Joint Committee on Cancer (AJCC) staging system, compared to placebo plus chemo.

Tecentriq was also tested for secondary endpoints including benefit in overall survival, disease-free survival and quality of life, but specific details in these measures were not revealed. Roche and Genentech instead confirmed that full results would be presented at an upcoming medical event.

“Triple-negative breast cancer remains an aggressive disease with high rates of recurrence,” commented Dr Levi Garraway, Chief Medical Officer and Head of Global Product Development. “Our goal in treating TNBC at its earliest stages is to provide people with the best chance for a future cure. Adding Tecentriq to chemotherapy now has the potential to help women with TNBC at multiple different stages of the disease.”

Matt Fellows


Mission Statement is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches